Results 141 to 150 of about 398,602 (339)
Practices of brand extensions and how consumers respond to FMCG giants’ greening attempts [PDF]
, 2022 Andreas Hesse +3 more
openalex +1 more source
Molecular Oncology, EarlyView.Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed +8 more
wiley +1 more source
Why Do Patients Move from Online Health Platforms to Hospitals? The Perspectives of Fairness Theory and Brand Extension Theory. [PDF]
Int J Environ Res Public Health, 2019 Le W, Chang PY, Chang YW, Chen J.
europepmc +1 more source
The Effectiveness of Image and Attitude on Extension Brand Loyalty in the Foodservice Industry
, 2009 권금택
openalex +1 more source
The Effect of Brand Extension Strategies upon Competitive Advantage in Service Companies from Costumers point of View [PDF]
, 2013 Bahram Ranjbarian +2 more
openalex +1 more source
ANALYSIS OF CONSUMERS'ATTITUDES TOWARD BRAND EXTENSION QUALITY [PDF]
, 2022 Le Nguyen Doan Khoi, Tu Van Binh
openalex +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
Unraveling LINE‐1 retrotransposition in head and neck squamous cell carcinoma
Molecular Oncology, EarlyView.The novel RetroTest method allows the detection of L1 activation in clinical samples with low DNA input, providing global L1 activity and the identification of the L1 source element. We applied RetroTest to a real‐world cohort of HNSCC patients where we reported an early L1 activation, with more than 60% of T1 patients showing L1 activity.
Jenifer Brea‐Iglesias +12 more
wiley +1 more source